Envista Holdings Corporation research snapshot
NVST AI stock analysis reads Envista Holdings as a global dental products company whose Q1 2026 results showed accelerating growth, margin expansion, and a new $300 million buyback, but whose balance sheet is net debt, not net cash, after the 2024 write-downs. This analysis is not a certain stock price prediction. At the August 3, 2026 cutoff, NVST traded near $27.46 intraday, up 0.55% from the $27.31 close on July 31, 2026, with a verified market capitalization of about $4.47 billion and an enterprise value of about $4.95 billion. TTM revenue was about $2.81 billion, up 12.15%, and TTM free cash flow was about $220 million, which is roughly 5% of the market cap. The stock trades above both the 50-day moving average near $25.48 and the 200-day moving average near $24.33, but remains below the 52-week high of $30.42. The main question is whether the Q1 2026 momentum in core sales, adjusted EBITDA, and adjusted EPS can continue into the August 5, 2026 Q2 report and support a forward P/E near 19x and an EV/EBITDA near 13.9x. This page is for informational use only and does not constitute investment advice.
Current price
$27.46 intraday on August 3, 2026, up about 0.55% from the $27.31 July 31 close
Market cap
$4.47 billion
AI score
60 / 100
Rating
Improving dental turnaround with strong free cash flow and a net debt balance sheet
Trend status
Above the 50-day and 200-day moving averages, consolidating below the 52-week high with an August 5 Q2 2026 earnings catalyst
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Envista sells dental implants, orthodontic systems, imaging equipment, and consumables to dentists and labs globally. Q1 2026 sales of $706 million grew 9.5% on a core basis, with 8.4% core growth in Specialty Products & Technologies and 11.5% core growth in Equipment & Consumables, showing broader-based momentum after the 2024 low. | Medium-high |
| Moat | Moat comes from the installed equipment base, consumables pull-through, brand recognition (Nobel Biocare, Ormco, Kerr, DEXIS), and digital workflow integration. Competition from Straumann, Align Technology, and Dentsply Sirona still limits pricing power in implants and clear aligners. | Medium |
| Management | CEO Paul Keel has driven operational improvements through the Envista Business System, with Q1 2026 gross margin and adjusted EBITDA margin up about 100 bps and 120 bps respectively, and a new $300 million buyback authorized on May 5, 2026. The board authorized the buyback through December 31, 2029. The track record under current leadership is still being established. | Medium |
| Financial trend | TTM revenue near $2.81 billion, up 12.15%, with TTM gross margin near 55% and TTM free cash flow near $220 million. Adjusted diluted EPS guidance for 2026 is $1.35 to $1.45. The balance sheet is net debt of about $506 million, a material change from the prior net cash framing, driven by $1.59 billion of total debt against $1.08 billion of cash. | Medium-high |
| Valuation | TTM P/E of 67.76x is distorted by low GAAP earnings after impairment charges. Forward P/E near 19.17x, EV/EBITDA near 13.87x, and P/FCF near 20.18x are more representative. FCF yield near 4.95% offers support, but the multiple leaves limited margin of safety for a turnaround in a competitive dental market. | Medium |
| Technical trend | NVST trades at $27.46 intraday, above the 50-day moving average near $25.48 and the 200-day moving average near $24.33, and up about 36.82% over 52 weeks. It pulled back from a July 29 intraday high near $28.85 and remains below the 52-week high of $30.42. 14-day RSI near 56 to 58 is neutral. | Medium-high |
| Risk level | Key risks are competitive pressure from Align Technology and Straumann, consumer spending sensitivity on elective dental procedures, China macro exposure, a net debt balance sheet, an Altman Z-score near 1.65, and the possibility that the Q2 2026 report disappoints against improved expectations. | Medium-high |
| AI confidence | High confidence for the business model, balance sheet, cash flow, market cap math, and technical snapshot. Lower confidence for precise earnings timing, the August 5 report, and competitive dynamics in clear aligners. | High data confidence, medium forecast confidence |
| Investment certainty | Low to medium. The company has improving momentum, real free cash flow, and a growing buyback, but the turnaround depends on sustained execution across several quarters, and the balance sheet is net debt, not net cash. | Low to medium |
NVST AI stock forecast
NVST stock forecast scenarios are built around the 2026 adjusted EPS guidance of $1.35 to $1.45 and the August 5 Q2 2026 report. The bull case depends on continued core sales growth near or above 9%, adjusted EBITDA margin expansion, Spark clear aligner profitability, and buyback support. The bear case centers on competition, weaker dental procedure volumes, and multiple compression. These are scenario ranges, not guaranteed price targets.
$30 - $38
More likely if Q2 2026 core sales growth stays near 9% to 10%, adjusted EBITDA margin keeps expanding, Spark clear aligners gain share, China recovers, and the market re-rates the stock toward a 21x to 24x forward P/E. The $34 BofA target and the $33 Evercore ISI target published in mid-2026 support this path, and a close above the $30.42 52-week high would confirm it.
$24 - $30
More likely if the company delivers against the 2026 adjusted EPS guidance of $1.35 to $1.45, core sales growth moderates toward the 2% to 4% full-year guidance range, and the stock holds a forward P/E near 17x to 20x. This zone spans the consensus target of $29.43, the median target of $30, and the Piper Sandler target of $26.
$16 - $24
More likely if dental procedure volumes weaken, Align Technology or Straumann take further share, the August 5 report disappoints, China volumes stay soft, or the market applies a lower multiple because the balance sheet is net debt and GAAP earnings remain low. The $21 low analyst target and the $18.77 52-week low mark the downside reference zone.
NVST AI technical analysis
NVST AI technical analysis shows the stock in a medium-term uptrend after bottoming near the 52-week low of $18.77. It trades above the 50-day and 200-day moving averages and has held gains from the Q1 2026 earnings report. The stock consolidated between roughly $25 and $28.85 through July and is facing the $30.42 52-week high. Levels below are from the August 3, 2026 Barchart and StockAnalysis.com snapshots; traders should confirm them on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $27.46 | StockAnalysis.com real-time snapshot on August 3, 2026, up 0.55% from the $27.31 July 31 close, which is the last verified daily close before this cutoff. |
| Support 1 | $26.00 to $26.50 | The July 27 to July 31 consolidation zone. A pullback into this area on normal volume would keep the uptrend structure intact. |
| Support 2 | $25.20 to $25.60 | The 50-day moving average is near $25.48 on StockAnalysis.com and $25.55 on Barchart. A break below this level would signal short-term momentum loss. |
| Support 3 | $24.20 to $24.40 | The 200-day moving average near $24.33 on StockAnalysis.com and $24.37 on Barchart. This is the key medium-term trend reference. |
| Resistance 1 | $28.00 to $28.85 | The July 29 intraday high near $28.85 and the prior overhead zone. A close above this area with volume would open the path toward the 52-week high. |
| Resistance 2 | $30.42 | The 52-week high. A break above this level would signal a new uptrend leg and could draw momentum buyers. |
| 50-day MA | $25.48 to $25.55 | StockAnalysis.com reported the 50-day near $25.48 and Barchart near $25.55. The stock is trading above this level, indicating positive short-term momentum. |
| 200-day MA | $24.33 to $24.37 | The 200-day moving average sits below the current price and confirms the medium-term trend has turned positive. |
| Momentum | RSI near 57 to 58, ADX near 14 to 17 | 14-day RSI near 57.98 on Barchart and 56.66 on StockAnalysis.com, neutral. 14-day ADX near 17.48 with +DI near 28.84 above -DI near 19.48 reflects a weak-to-moderate uptrend with positive directional pressure. |
| Volume trend | Improving, with a July 29 spike | 20-day average volume near 2.63 million shares. Volume spiked to about 6.05 million on July 29, 2026, when the stock rose 5.23%, showing institutional interest near the $28 level. |
| Volatility | Beta 0.86, 14-day historic volatility near 30% | Beta below 1.0 means NVST has been less volatile than the market on average, but 14-day historic volatility near 29.5% to 32% shows meaningful short-term swings around events. |
| Invalidation level | Close below $24.20 | A break below the 200-day moving average zone near $24.20 to $24.40 would weaken the medium-term uptrend thesis and suggest a return to the lower $22 to $24 range. |
NVST AI trading strategy
NVST AI trading strategy framework treats the stock as a trend-following candidate above its moving averages with an August 5, 2026 earnings event risk. The setups below are analytical frameworks for research, not personalized trading advice.
Look for NVST to hold the $26.00 to $26.50 support zone and reclaim the $28.00 to $28.85 area with above-average volume before treating the post-July consolidation as resolved. The $30.42 52-week high is the extended target.
Risk 5% to 7% per position. Invalidate the setup on a daily close below the 200-day moving average near $24.20 to $24.40, or on a failed reclaim of $28 that leads to lower highs.
On pullbacks toward the 50-day moving average near $25.20 to $25.60, look for oversold RSI readings (below 40) and a stabilizing volume pattern before entering. Target a return to the $27 to $28 range over two to four weeks, with the $30.42 high as the extended target.
Size positions at 60% of normal because the stock carries event risk and has shown 3% to 5% single-day swings. Invalidate on a close below $24.20, which would signal a structural rather than cyclical pullback.
NVST reports Q2 2026 on August 5, 2026 after market close, and results historically drive 3% to 6% single-day moves. The August 5 report is the dominant near-term catalyst, followed by the Investor Day on September 17, 2026. Position only if the setup aligns with support or resistance levels.
Reduce position size before earnings or use defined-risk option strategies. The implied move around the report is uncertain because expectations have risen after the Q1 2026 beat and the $300 million buyback announcement.
Investment research summary
Envista sells dental products and digital workflow solutions to dental professionals through brands like Nobel Biocare, Ormco, Kerr, and DEXIS. Customers pay for reliable instruments, consumables, imaging, and software that improve clinical outcomes and practice efficiency. Q1 2026 core sales growth of 9.5% shows the business is growing again after the 2024 trough.
The moat is moderate and relies on installed equipment, consumables pull-through, brand heritage, and digital workflow integration. The moat is not visibly widening as competitors invest aggressively in clear aligners, CBCT imaging, and chairside workflows, and the 2024 write-down reflected softer growth in parts of the portfolio.
The thesis fails if Spark clear aligners cannot achieve sustainable profitability against Invisalign, if Straumann takes additional implant share, if China volumes remain structurally lower, if dental procedure volumes slow, or if the net debt position combined with weaker earnings forces deleveraging that limits buyback capacity.
CEO Paul Keel has prioritized operational execution through the Envista Business System, with Q1 2026 adjusted EBITDA up 25% and adjusted diluted EPS up 50% on strong core growth. The board authorized a new $300 million buyback on May 5, 2026, signaling confidence, and the company repurchased about 1.6 million shares for about $43 million in Q1 2026. Key-person risk exists given the relatively recent CEO transition, and the capital allocation track record under current leadership is still being built.
Dental is a steady-growth industry driven by aging demographics, cosmetic dentistry demand, and digital workflow adoption. Clear aligners and guided implant surgery are secular growth areas. The industry is cyclical with consumer spending and dental insurance coverage, and Envista is a mid-size player competing against larger dental peers.
At $27.46, NVST trades near 19.17x forward earnings, 13.87x EV/EBITDA, and 20.18x trailing free cash flow with an FCF yield near 4.95%. The 2026 adjusted EPS guidance of $1.35 to $1.45 anchors the forward multiple. The balance sheet is net debt of about $506 million, so the margin of safety depends on whether earnings normalize toward guidance in the next two years and on the August 5 report outcome.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NVST price | $27.46 real-time on August 3, 2026, up about 0.55% from the $27.31 close on July 31 | StockAnalysis.com real-time quote snapshot | August 3, 2026 |
| Market capitalization | $4.47 billion, verified as $27.46 x 162.73 million shares (0.03% deviation) | financial_rigor.py market cap verification and StockAnalysis.com | August 3, 2026 |
| Enterprise value | $4.95 billion | StockAnalysis.com statistics | August 3, 2026 |
| TTM revenue | $2.81 billion, up 12.15% | StockAnalysis.com statistics and financials | August 3, 2026 |
| TTM net income | $67.70 million (StockAnalysis.com statistics), EPS $0.41 | StockAnalysis.com statistics | August 3, 2026 |
| TTM free cash flow | $220.20 million, from operating cash flow of $272.10 million less capital expenditures of $51.90 million | StockAnalysis.com statistics and cash flow statement | August 3, 2026 |
| Cash and equivalents | $1.08 billion at April 3, 2026 | StockAnalysis.com balance sheet | August 3, 2026 |
| Total debt | $1.59 billion, including about $1.44 billion of long-term debt and lease liabilities | StockAnalysis.com balance sheet | August 3, 2026 |
| Net cash (debt) | -$506.40 million, or about -$3.11 per share, a net debt position at April 3, 2026 | StockAnalysis.com statistics and balance sheet | August 3, 2026 |
| P/E (TTM) | 67.76x | StockAnalysis.com statistics | August 3, 2026 |
| Forward P/E | 19.17x | StockAnalysis.com statistics | August 3, 2026 |
| EV/EBITDA | 13.87x | StockAnalysis.com statistics | August 3, 2026 |
| P/FCF (TTM) | 20.18x, with FCF yield near 4.95% | StockAnalysis.com statistics and financial_rigor.py verification | August 3, 2026 |
| Q1 2026 results | Sales of $706 million with 9.5% core sales growth, GAAP diluted EPS of $0.23, adjusted diluted EPS of $0.36, up 50%, adjusted EBITDA of $99 million, up 25%, and adjusted EBITDA margin of 14.0% | Envista Q1 2026 results via PR Newswire | August 3, 2026 |
| Q1 2026 segment core growth | Specialty Products & Technologies core growth of 8.4% and Equipment & Consumables core growth of 11.5% | Envista Q1 2026 results via PR Newswire | August 3, 2026 |
| Q1 2026 cash flow | Operating cash flow of negative $3 million and free cash flow of negative $16 million in Q1 2026 | Envista Q1 2026 results via PR Newswire | August 3, 2026 |
| 2026 guidance | Core sales growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, adjusted diluted EPS of $1.35 to $1.45, and free cash flow conversion near 100% | Envista Q1 2026 results via PR Newswire | August 3, 2026 |
| Share repurchase | About 1.6 million shares repurchased for about $43 million in Q1 2026, with a new $300 million authorization announced May 5, 2026 | Envista Q1 2026 results via PR Newswire | August 3, 2026 |
| Analyst consensus | Buy, 16 analysts, average target $29.43, low $21, median $30, high $35 | StockAnalysis.com forecast and S&P Global | July 30, 2026 |
| Recent analyst target updates | BofA raised to $34 from $28 with a Buy on July 30, 2026; Piper Sandler raised to $26 from $25 with a Hold on July 29, 2026; BMO Capital initiated with a Market Perform and $27 target on July 8, 2026; Barclays lowered to $32 from $34 with an Overweight on June 11, 2026; Evercore ISI raised to $33 from $30 with an Outperform; JPMorgan raised to $29 from $26 with a Neutral; Baird raised to $31 from $30 with an Outperform | StockAnalysis.com forecast and TheFly via TipRanks | August 3, 2026 |
| FY26 and FY27 consensus estimates | FY26 revenue estimate about $2.86 billion with adjusted EPS about $1.43, FY27 revenue about $2.96 billion with EPS about $1.57 | StockAnalysis.com forecast | July 30, 2026 |
| 52-week range and performance | 52-week range $18.77 to $30.42, up about 36.82% over 52 weeks, beta 0.86 | StockAnalysis.com quote and statistics | August 3, 2026 |
| Short interest | 9.36 million shares, about 5.75% of shares outstanding, about 3.44 days to cover | StockAnalysis.com statistics | August 3, 2026 |
| Technical snapshot | 5-day SMA near $27.58, 20-day SMA near $26.72, 50-day SMA near $25.48 to $25.55, 100-day SMA near $25.62, 200-day SMA near $24.33 to $24.37, 14-day RSI near 56.66 to 57.98, 14-day ADX near 17.48, 14-day historic volatility near 29.5% | Barchart and StockAnalysis.com technical snapshots | August 3, 2026 |
This NVST AI stock analysis page is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All forecast scenarios are based on publicly available data and analytical assumptions that may prove incorrect. Past performance is not indicative of future results. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Data cutoff: August 3, 2026. Prices and metrics may have changed since this date.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
